NEW YORK, Oct. 2 - Young, private genomic companies in the US anxious about a constricting venture capital market can breathe easy.

Despite sharp drops in the stock market, a receding overall venture capital tide, and the economic uncertainty brought on by the terrorist assault on the US three weeks ago, industry analysts believe that the private equity environment for early-stage genomic companies remains robust, has been outperforming the overall VC market, and shows signs of growth in the new year.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.